Galanin and Galanin Receptor Expression in Neuroblastic Tumours: Correlation with Their Differentiation Status

Overview

Journal Br J Cancer

Specialty Oncology

Date 2002 Feb 22

PMID 11857022

Citations 10

Authors

Y Perel

L Amrein

E Dobremez

J Rivel

J Y Daniel

M Landry

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma and its benign differentiated counterpart, ganglioneuroma, are paediatric neuroblastic tumours arising in the sympathetic nervous system. Their broad spectrum of clinical virulence is mainly related to heterogeneous biologic background and tumour differentiation. Neuroblastic tumours synthesize various neuropeptides acting as neuromodulators. Previous studies suggested that galanin plays a role in sympathetic tissue where it could be involved in differentiation and development. We investigated the expression and distribution of galanin and its three known receptors (Gal-R1, Gal-R2, Gal-R3) in 19 samples of neuroblastic tumours tissue by immunohistochemistry, in situ hybridization and fluorescent-ligand binding. This study provides clear evidence for galanin and galanin receptor expression in human neuroblastic tumours. The messengers coding for galanin, Gal-R1 and -R3 were highly expressed in neuroblastoma and their amount dramatically decreased in ganglioneuroma. In contrast, Gal-R2 levels remained unchanged. Double labelling studies showed that galanin was mainly co-expressed with its receptors whatever the differentiation stage. In neuroblastic tumours, galanin might promote cell-survival or counteract neuronal differentiation through the different signalling pathways mediated by galanin receptors. Finally, our results suggest that galanin influences neuroblastoma growth and development as an autocrine/paracrine modulator. These findings suggest potential critical implications for galanin in neuroblastic tumours development.

Citing Articles

Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma.

Wang J, Zhang H, Yan Z, Cao Z, Shao J, Zou L Discov Oncol. 2024; 15(1):456.

PMID: 39292372 PMC: 11410741. DOI: 10.1007/s12672-024-01318-0.

A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma.

Ma K, Zhang P, Xia Y, Dong L, Li Y, Liu L BMC Med Genomics. 2022; 15(1):242.

PMID: 36419120 PMC: 9685875. DOI: 10.1186/s12920-022-01400-y.

The Galaninergic System: A Target for Cancer Treatment.

Sanchez M, Covenas R Cancers (Basel). 2022; 14(15).

PMID: 35954419 PMC: 9367524. DOI: 10.3390/cancers14153755.

Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer.

Wu M, Yuan K, Lyu S, Li Y World J Surg Oncol. 2022; 20(1):214.

PMID: 35751103 PMC: 9229513. DOI: 10.1186/s12957-022-02683-2.

Galanin System in Human Glioma and Pituitary Adenoma.

Falkenstetter S, Leitner J, Brunner S, Rieder T, Kofler B, Weis S Front Endocrinol (Lausanne). 2020; 11:155.

PMID: 32265844 PMC: 7105811. DOI: 10.3389/fendo.2020.00155.

References

Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H . NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol. 1997; 15(12):3433-40. DOI: 10.1200/JCO.1997.15.12.3433. View

Del Fiacco M, Quartu M . Somatostatin, galanin and peptide histidine isoleucine in the newborn and adult human trigeminal ganglion and spinal nucleus: immunohistochemistry, neuronal morphometry and colocalization with substance P. J Chem Neuroanat. 1994; 7(3):171-84. DOI: 10.1016/0891-0618(94)90027-2. View

Hulting A, Land T, Berthold M, Langel U, Hokfelt T, Bartfai T . Galanin receptors from human pituitary tumors assayed with human galanin as ligand. Brain Res. 1993; 625(1):173-6. DOI: 10.1016/0006-8993(93)90152-d. View

Marinissen M, Gutkind J . G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci. 2001; 22(7):368-76. DOI: 10.1016/s0165-6147(00)01678-3. View

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P . N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol. 1997; 15(3):1171-82. DOI: 10.1200/JCO.1997.15.3.1171. View

Invitti C, Pecori Giraldi F, Dubini A, Moroni P, Losa M, Piccoletti R . Galanin is released by adrenocorticotropin-secreting pituitary adenomas in vivo and in vitro. J Clin Endocrinol Metab. 1999; 84(4):1351-6. DOI: 10.1210/jcem.84.4.5629. View

Zigmond R, Sun Y . Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences. Ann N Y Acad Sci. 1997; 814:181-97. DOI: 10.1111/j.1749-6632.1997.tb46157.x. View

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

Evangelista L, Swartzman E, Miraglia S, WERNER W, Yuan P . Determination of ligand binding affinities for endogenous seven-transmembrane receptors using fluorometric microvolume assay technology. Anal Biochem. 1999; 272(2):182-90. DOI: 10.1006/abio.1999.4175. View

10.

Bartfai T, Hokfelt T, Langel U . Galanin--a neuroendocrine peptide. Crit Rev Neurobiol. 1993; 7(3-4):229-74. View

11.

Amiranoff B, Loquet I, Laburthe M, Mayaux J . Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci U S A. 1994; 91(21):9780-3. PMC: 44900. DOI: 10.1073/pnas.91.21.9780. View

12.

Sethi T, Langdon S, Smyth J, Rozengurt E . Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res. 1992; 52(9 Suppl):2737s-2742s. View

13.

Sano T, Vrontakis M, Kovacs K, Asa S, Friesen H . Galanin immunoreactivity in neuroendocrine tumors. Arch Pathol Lab Med. 1991; 115(9):926-9. View

14.

Kolakowski Jr L, ONeill G, Howard A, Broussard S, Sullivan K, Feighner S . Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem. 1998; 71(6):2239-51. DOI: 10.1046/j.1471-4159.1998.71062239.x. View

15.

Bjellerup P, Theodorsson E, Jornvall H, Kogner P . Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours. Br J Cancer. 2000; 83(2):171-6. PMC: 2363490. DOI: 10.1054/bjoc.2000.1234. View

16.

McKnight G, Karlsen A, Kowalyk S, Mathewes S, Sheppard P, OHara P . Sequence of human galanin and its inhibition of glucose-stimulated insulin secretion from RIN cells. Diabetes. 1992; 41(1):82-7. DOI: 10.2337/diab.41.1.82. View

17.

Albers A, ODorisio M, Balster D, CAPRARA M, Gosh P, Chen F . Somatostatin receptor gene expression in neuroblastoma. Regul Pept. 2000; 88(1-3):61-73. DOI: 10.1016/s0167-0115(99)00121-4. View

18.

Nakagawara A, Brodeur G . Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur J Cancer. 1998; 33(12):2050-3. DOI: 10.1016/s0959-8049(97)00280-3. View

19.

Burazin T, Larm J, Ryan M, Gundlach A . Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. Eur J Neurosci. 2000; 12(8):2901-17. DOI: 10.1046/j.1460-9568.2000.00184.x. View

20.

Heasley L . Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene. 2001; 20(13):1563-9. DOI: 10.1038/sj.onc.1204183. View